How can we seize opportunities in ever-changing markets?

Their CTX001 (cure for sickle cell / Beta Thalassemia) will get approved in 2022. Good pipeline in Oncology. There has been a significant pull back in biotech, including this equity. Current Market Cap is 6.2 billion, they have 2.5 billion in Cash. Can easily 2x.